We believe in the potential
of every human being to
live without limits

Sen-Jam is a catalyst for change.

Sen-Jam innovates to eliminate painful side effects, whether they come from medicine or everyday living.

Life is an adventure, meant to be enjoyed both responsibly and fully. Our goal is to create value by finding novel Pharmaceutical solutions for large, unmet needs while forging global sales, distribution, and licensing agreements with like-minded agents of positive change–companies and innovators that want to make the world a better place. We are currently collaborating with several great partners and welcome conversations to explore possibilities with new ones. Sen-Jam innovates to eliminate many painful side effects. Whether they come from medicine or everyday living. Our product line is based on Opioid Free Pain Relief with GI Protection for Extended Use.

Icon Smiley

We are passionate about helping people live well, championing happier, healthier, more productive, less pain-filled lives.

Icon Magnifier

We are dedicated to constant improvement, pursuing intellectual and medical curiosity, perpetual learning and innovation.

Icon Reimagining

We are fearlessly reimagining connections, bringing people and organizations together through open communication.

Icon Warning

We are relentless about efficacy and safety, supporting only products with clinically proven benefits that outweigh any risk.

Our Leadership Team

Dedicated to ridding the world of side-effects

Jacqueline Iversen

Jacqueline Iversen, RPh, MS

Head of Clinical Development

Jackie has extensive knowledge and capabilities in a multitude of clinical settings. Her expertise involves providing clinical education across the healthcare continuum. She also completed a research fellowship in pharmacokinetics and pain at Memorial Sloan Kettering Cancer Center.

Jim Iversen

Jim Iversen

CEO/COO

Jim is a Senior Executive with a consistent track record of developing and executing business strategies that deliver rapid growth in sales, profits, market share, employee and customer satisfaction. Client engagements range from start-ups to late stage, often resulting in an M&A transaction.

Thomas Dahl

Thomas Dahl, PhD

Head of Product Development and Regulatory Affairs

Tom has held several senior management positions with companies ranging from start-ups to established global companies. He is an accomplished biotech/pharmaceutical executive with expertise in early stage ventures, including technical analysis of products and technologies, business strategy and operations, development program strategy, clinical trial design and interpretation, and interfacing with pharmaceutical partners.

Scientific Advisory Board

Thomas Dahl

Thomas Dahl, PhD

Biotech Executive & Consultant
Tom is an accomplished biotech/pharmaceutical executive with expertise in early stage ventures, including technical analysis of products and technologies, business strategy and operations, development program strategy, clinical trial design and interpretation, and interfacing with pharmaceutical partners.

Joris Verster

Joris Verster, PhD

Utrecht University
Joris has extensive experience as principal investigator of clinical trials examining the effects of drugs on driving, cognitive effects of food and (medicinal) drugs, alcohol hangover, and sleep and sleep disorders. He is founder of the Alcohol Hangover Research Group, and scientific advisor of various pharmaceutical companies.

Andrew Scholey

Andrew Scholey

Swinburne University
Andrew is a leading international researcher into the neurocognitive effects of natural products, supplements and food components. He is the founder of the Human Cognitive Neuroscience Unit at Northumbria University, UK.

Gary Zammit

Gary Zammit, PhD

Clinilabs
Gary specializes in early phase and specialty clinical drug development. He is the founder of Clinilabs and a key opinion leader for clinical development outsourcing.

Frank Farraye

Francis Farraye

Mayo Clinic
Francis Farraye, MD, MSC Senior Associate Consultant in Gastroenterology and Hepatology at the Mayo Clinic where he co-directs the Inflammatory Bowel Disease Center.

Advisory Board

Douglas Hammond

Douglas W. Hammond

Chairman and Chief Executive Officer, NFP
DOUG HAMMOND, Chairman and CEO, NFP, led NFP’s pivotal $1.4 billion go-private transaction with Madison Dearborn Partners LLC (MDP), a leading private equity firm. Doug subsequently led two recapitalizations on NFP, in 2017 and 2019, the most recent of which valued the company at $5.8 billion and created significant opportunities for future growth.